by Richard Daverman, PhD
September 29, 2012 -- China Kanghui Holdings will be acquired by fellow medical device maker Medtronic for $816 million; China Nuokang Bio-Pharma accepted a go-private offer that values the company at $114 million; Medicago, a Canadian vaccines company, has out-licensed China rights to its pandemic and seasonal flu vaccines to cigarette maker Philip Morris Products in a $12 million deal; BGI of Shenzhen will build a next generation sequencing facility in Singapore in a diagnostics partnership with INEX Innovations; Novo Nordisk officially opened a new $100 million R&D center in Beijing; Neuralstem was granted SFDA approval to begin a clinical trial in China of its spinal cord stem cell product as a treatment for stroke; and the BayHelix Group together with Elsevier Business Intelligence handed out four awards for innovation in China pharma development. More details….
Stock Symbols: (NYSE: KH) (NYSE: MDT) (NSDQ: NKBP) (TSX: MDG) (NYSE: NVO) (NYSE: CUR)
